(Q36346641)

English

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

Douglas A Levine

object named as

Douglas A Levine

19

1 reference

ORCID Public Data File 2021

David Gershenson

17

object named as

David M Gershenson

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Rachel N. Grisham

1

object named as

Rachel N Grisham

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

11

object named as

Vicky Makker

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Carol Aghajanian

23

object named as

Carol A Aghajanian

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

Brooke E Sylvester

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Helen Won

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Gregory McDermott

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Deborah DeLair

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Ricardo Ramirez

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Zhan Yao

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Ronglai Shen

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Fanny Dao

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Faina Bogomolniy

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Evis Sala

12

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Tara E Soumerai

13

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

David M Hyman

14

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Nicholas D Socci

15

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Agnes Viale

16

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

John Farley

18

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Neal Rosen

20

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Michael F Berger

21

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

David R Spriggs

22

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

David B Solit

24

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Gopa Iyer

25

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

31 August 2015

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

33

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

34

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

4099-4105

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Whole exome sequence analysis of serous borderline tumors of the ovary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Low-grade serous carcinomas of the ovary contain very few point mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Integrated genomic analyses of ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

30 September 2017

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

22 September 2018

MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

22 September 2018

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

22 September 2018

The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

22 September 2018

Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4669594

22 September 2018

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26324360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/26324360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

1 reference

https://pubmed.ncbi.nlm.nih.gov/26324360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2015.62.4726

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36346641&oldid=2047140113"